Oncología y Hematología Clínica Pediátrica

Pediatric Diffuse Midline Glioma (DMG) International Meeting

Inscripciones cerradas


Would you like to learn more about one of the most devastating brain tumor in children? Would you like to learn about the latest scientific and clinical advances being made to combat this disease? Are you interested in hearing the experiences and advice of the best international experts in the field of pediatric neuro-oncology? If your answer is yes, you cannot miss this course on diffuse midline glioma, a unique opportunity to expand your knowledge and skills on this important and current topic.

Diffuse midline glioma is a type of cancer that mainly affects children and adolescents, originating in the deepest and most vital areas of the brain, such as the brain stem or thalamus. It is a very aggressive tumor that is resistant to conventional treatments and is characterized by a specific genetic mutation that alters the expression of histones, proteins that regulate the structure and function of DNA. This mutation causes the tumor to grow rapidly and cause severe symptoms, such as problems with vision, speech, movement, or breathing. The prognosis for these patients is very poor, and the average survival is less than one year.

In this course, you will have the opportunity to learn everything you need to know about diffuse midline glioma, from its epidemiology, diagnosis, prognosis and treatment, to the challenges and future prospects for research and innovation in this neoplasm. In addition, you will be able to interact with different international experts who will share their knowledge, experiences, and advice on how to deal with this type of tumor.

Among them, we will have the presence of the renowned pediatric neuro-oncology Roger Packer, director of the Brain Tumor Institute at the Children's National Hospital in Washington DC, and Dr. Sabine Mueller, Professor of Neurology, Neurosurgery and Pediatrics, UCSF; leader of the Pacific Pediatric Neuro-Oncology (PNOC) group, among other relevant experts, lead who will talk about the latest clinical trials and new targeted therapies being developed for diffuse midline glioma.

Don't miss this unique opportunity to be updated about diffuse midline glioma, and the ongoing initiatives aiming to change the fate of the children and adolescents suffering from this brain cancer.

Register now, we are waiting for you!

Dirigido a

  • Oncologists.
  • Cancer researchers. 
  • Anatomo-pathologists. 
  • Radiotherapeutic Oncologist. 
  • Neuro-radiologist. 
  • Neurosurgeons. 
  • Biologist in health sciences. 
  • Biochemists in health sciences. 
  • Hospital pharmacists. 
  • Chemists in health sciences.


  • To update knowledge about DMG/DIPG. 
  • To improve the competence of professionals caring for children and adolescents with malignant midline gliomas. 
  • To optimize the treatment of these patients and promote their participation in clinical trials. 
  • To know the current clinical trials and their results.


October 16, 2023

  • Part 1: Pediatric Neurooncology Landscape in Spain.
    • Overview: Pediatric brain tumors and distribution of treating centers.
    • Precision Medicine Program. PENCIL.
    • Early Clinical Trials in Neuro-Oncology.
    • Opening Clinical Trials in Spain: Costs and regulations.
  • Part 2. DMG Trials in Spain.
    • Mesenchymal cells + Oncovirus (Celyvir) trial for DIPG.
    • Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma.
    • Dendritic cell Vaccination + CART antilL13Ralpha2 for DIPG.
    • Tumor Board DMG (Selected case presentations TBC).
  • Part 3. DMG Research and Clinical Trials. Part 1.
    • Clinical trials with Novel therapeutic approaches for patients with DMG at Children's National Hospital.
    • PNOC Trials for DMG/DIPG.
    • CAR-T Cells in DMG.

October 17, 2023

  • Part 3. DMG Research and Clinical Trials. Part 2.
    • Basic and translational research in DMG.
    • ONC 201 and Histone dysregulation.
    • Development of CNS-penetrant medicines for DMB.
    • Gate2Brain Technology from Discovery to Application in Pediatric Brain Tumors with Intact Blood Brain Barrier such as DMGs.
    • Patient Family's voices.
    • Wrap up and adjourn.

Descargar programa



€50 in face-to-face format.

€30 in online format.

With the endorsement

With the sponsorship

Información clave

Dirección Formación Hospital Sant Joan de Déu
Carrer de Santa Rosa, 39-57
08950 Esplugues de Llobregat
Oncología y Hematología Clínica Pediátrica
Idioma Inglés
Horas lectivas 10,5 h
Acreditación Training activity accredited by the Consell Català de Formació Continuada Professions Sanitàries-Comisión de Formación Continuada del Sistema Nacional de Salud
Código: 09/035606-MD
Horas acreditadas: 10,50 h
Créditos: 1,3